Clinical Trial Update: Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating peanut oral immunotherapy alone and in combination with an anti-IgE approach for peanut allergy has completed, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Omalizumab (Omalizumab)
• Peanut oral immunotherapy (peanut OIT)

Snippet

Sponsor: University of North Carolina, Chapel Hill | Conditions: Peanut Hypersensitivity | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-09-26